Clinical Trials Browser

Phase 1/2 × Bendamustine Hydrochloride × 1 year × Clear all

NCT07225985 2026-03-06

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell

NCT04663347 2026-03-03

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05551936 2026-02-17

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT05300282 2026-01-28

FIL_A-BEGEV

Phase 1/2 Recruiting

Hodgkin Disease, Recurrence

NCT04022239 2026-01-12

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Phase 1/2 Recruiting

Hematopoietic and Lymphoid System Neoplasm

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Hodgkin Disease

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT04673617 2025-06-11

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin